Yu, C.-H.; Chou, Y.-H.; Shieh, T.-Y.; Liu, C.-Y.; Wu, J.-M.; Hsieh, C.-H.; Lee, T.-H.; Chung, C.-S. Favorable Long-Term Outcomes of Early Esophageal Squamous Neoplasia with Muscularis Mucosa Involvement after Endoscopic Submucosal Dissection. Preprints2024, 2024070136. https://doi.org/10.20944/preprints202407.0136.v1
APA Style
Yu, C. H., Chou, Y. H., Shieh, T. Y., Liu, C. Y., Wu, J. M., Hsieh, C. H., Lee, T. H., & Chung, C. S. (2024). Favorable Long-Term Outcomes of Early Esophageal Squamous Neoplasia with Muscularis Mucosa Involvement after Endoscopic Submucosal Dissection. Preprints. https://doi.org/10.20944/preprints202407.0136.v1
Chicago/Turabian Style
Yu, C., Tzong-Hsi Lee and Chen-Shuan Chung. 2024 "Favorable Long-Term Outcomes of Early Esophageal Squamous Neoplasia with Muscularis Mucosa Involvement after Endoscopic Submucosal Dissection" Preprints. https://doi.org/10.20944/preprints202407.0136.v1
Abstract
Ambiguity exists over treatment and surveillance strategies after endoscopic submucosal dissec-tion (ESD) for esophageal squamous cell neoplasia (ESCN) with unfavorable histologic features. This study investigated the long-term outcomes of ESD in high-risk ESCN patients. We retro-spectively included early ESCN patients treated with ESD at two medical centers in Taiwan be-tween August 2010 and December 2023. Demographic, endoscopic, and pathological data were collected. Among 146 patients (mean age 59.17 years) with 183 lesions, 73 (50%) had a history of head and neck cancer (HNC). En bloc and R0 resection were achieved in 100% and 95.6% of the lesions, respectively. The 5-year overall survival (OS), disease-specific survival (DSS) and local recurrence rates were 42.7%, 94.7% and 11%. R0 resection was significantly associated with re-currence in univariate analysis (adjusted OR: 0.23, 95% CI: 0.05-0.99, P=0.05). Alcohol abstinence was independently associated with lower recurrence (adjusted OR: 0.20, 95% CI: 0.08-0.48, P
Keywords
Esophageal squamous cell carcinoma; Endoscopic submucosal dissection; Second primary tumor; Head and neck cancer; Expanded indication
Subject
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
